Suche
Mein Konto
Revolution in medicine: Saliva test for individual therapies!
TimeTeller from Hamburg is researching saliva tests to optimize individual cancer therapies using circadian rhythms.
Revolution in medicine: Saliva test for individual therapies!
The Hamburg health tech startup TimeTeller has caused a stir with an innovative approach to measuring circadian rhythms. On September 23, 2025, it was announced that the company had developed a saliva test that would enable personalized therapy. This test is currently being researched and tested in several clinics in Germany with the aim of improving cancer therapies through individual knowledge of patients' internal biological clocks. Loud Medical School Hamburg is headed by co-founder Prof. Dr. Angela Relógio the project supported by the MSH (Modern Medical School).
Prof. Dr. Ilona Renken-Olthoff, founder of MSH, emphasizes the importance of innovative thinking in evidence-based, patient-centered care. TimeTeller was also a finalist for the German Founder Award in the “Start-up” category during the awards ceremony in Berlin.
Innovative diagnostic procedure
TimeTeller's diagnostic process is based on a saliva test that is combined with mathematical models, artificial intelligence (AI) and molecular biological evaluation. This procedure aims to change the paradigm in medicine by moving away from rigid schedules and towards personalized therapy. The use of the test is particularly relevant because medications do not work the same way at all times of the day. Circadian rhythms influence both the effects and side effects of medications. How German Founder Prize reports, TimeTeller has already achieved initial promising results in the treatment of chronic fatigue, Parkinson's disease and women's health.
Around 600 patients have already benefited from the clinical studies in which TimeTeller is used. These studies are taking place in both Germany and Portugal, and there are plans for further studies in Europe, the USA and Canada. Diagnostics are intended to help optimize individual treatment options and thus represent a significant development in the field of personalized medicine.
Awards and collaborations
In addition to its scientific achievements, TimeTeller was also recognized for its entrepreneurial achievements. The company received the Hamburg Founder's Prize 2025, awarded by the Hamburger Sparkasse and the Hamburger Abendblatt. There is a cooperation with the Techniker Krankenkasse in order to develop a prevention offer for the insured.
The product, which aims to provide recommendations for daily activities to improve health, is scheduled to be launched by the end of 2025. In addition, a fully developed and approved test to measure circadian rhythms is expected by 2028.
TimeTeller occupies a niche in the field of chronomedicine, as circadian rhythm disorders are listed as a separate diagnosis in the international ICD-10 classification. With this approach, TimeTeller could revolutionize not only the treatment of cancer, but also general healthcare.